Use of Continuous Glucose Monitoring in Pump Therapy Sensor Augmented Pump or Automated Insulin Delivery in Different Age Groups (0.5 to <26 Years) With Type 1 Diabetes From 2018 to 2021: Analysis of the German/Austrian/Swiss/Luxemburg Diabetes Prospective Follow-up Database Registry

• Published in: Journal of diabetes science and technology 2024-09, Vol.18 (5), p.1122-1131
• Main Authors: van den Boom, Louisa, Auzanneau, Marie, Woelfle, Joachim, Sindichakis, Marina, Herbst, Antje, Meraner, Dagmar, Hake, Kathrin, Klinkert, Christof, Gohlke, Bettina, Holl, Reinhard W.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Age Factors; Austria - epidemiology; Blood Glucose - analysis; Blood Glucose - drug effects; Blood Glucose Self-Monitoring - instrumentation; Child; Child, Preschool; Continuous Glucose Monitoring; Databases, Factual; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Female; Follow-Up Studies; Germany - epidemiology; Glycated Hemoglobin - analysis; Humans; Hypoglycemic Agents - administration & dosage; Infant; Insulin - administration & dosage; Insulin Infusion Systems; Luxembourg - epidemiology; Male; Original; Prospective Studies; Registries; Switzerland - epidemiology; Young Adult
• ISSN: 1932-2968; 1932-3107
• DOI: 10.1177/19322968231156601

Aim: Insulin pump, continuous glucose monitoring (CGM), and sensor augmented pump (SAP) technology have evolved continuously leading to the development of automated insulin delivery (AID) systems. Evaluation of the use of diabetes technologies in people with T1D from January 2018 to December 2021. Methods: A patient registry (Diabetes Prospective Follow-up Database [DPV]) was analyzed for use of SAP (insulin pump + CGM ≥90 days, no automated dose adjustment) and AID (HCL or LGS/PLGS). In total 46,043 people with T1D aged 0.5 to